Strategies of drug users to avoid infection with hepatitis C

Similar documents
Public drug policies Catalonia

Models of good practice in drug treatment in Europe. Project group

NEEDLE AND SYRINGE PROGRAMMES MONITORING IN LITHUANIA

Signs of success latest national NESI data?

Drug Consumption Rooms Worldwide

EMCDDA-update HIV/HCV among people who inject drugs: situation and response

The Imp.Ac.T.project. Improving Access to HIV/TB Testing for marginalized groups

From Fix to Foil. The Dutch experience in promoting transition away from injecting drug use,

Most recent data, analyses and feed-back from the 2016 DRID national updates

Trends in injecting drug use in Europe

Poland nationalupdate

HIV and Hepatitis C Infection among Persons who Inject Drugs: Global Overview and Policy Implications

Promoting hepatitis B vaccination

INTRAVENOUS INJECTING DRUG USE.

Injecting trends in Austria including results of a systematic literature review on interventions aiming to influence the route of administration

Innovative approaches for preventing infection with hepatitis c among drug users

Thirty years of harm reduction in the Netherlands HCV elimination ahead?

Hepatitis prevention in the context of HIV prevention point work in Latvia

Substance use and misuse

Drug Policy and the HIV Movement. SAULIUS CAPLINSKAS MD, PhD

First results collected by Argos, DCR in Strasbourg opened in november 2016

Detection of Hepatitis B and C in Primary Care

ANNUAL PROJECT PROGRESS REPORT FOR 2008 (draft)

Recent trends in drug problems and service provision in Greece

OST saves lives it s official! OST a key to HIV prevention Opioid Substitution Treatment in Germany A Story of Success

New trends in harm reduction in Europe: progress made challenges ahead

Guidelines For Services Providing Injecting Equipment

HIV/AIDS Joint Action HA-REACT

PERFORMANCE AND IMAGE ENHANCING DRUGS

Prevalence of HIV, HCV and other sexually transmitted infections and associated risk behaviours among Spanish and immigrant IDU in Catalonia, Spain

The epidemiology of HIV infection in Greece HIV/AIDS reporting system

HA-REACT Joint Action on HIV and coinfection. prevention and harm reduction

HIV in Prison Situation in Frankfurt am Main

2 nd Meeting on detecting and responding to outbreaks of HIV among PWID

Improving Access to Test and Counselling Services for Injection Drug Users: Most Recent Experience from Portugal. Henrique Barros

HIV/AIDS Think Tank meeting: EMCDDA report. Roland Simon, Klaudia Palczak, EMCDDA Luxembourg, 7 July 2015

Joint Action on HIV and co-infection prevention and harm reduction HA-REACT

Testing, Prevention and Care IDU in Chicago, 2009

High prevalence and incidence of HIV and HCV among new injecting drug users with a large proportion of migrants Is prevention failing?

Background. Population/Intervention(s)/ Comparison/Outcome(s) (PICO)

The Comprehensive Package: The simple truth about our response to drug related HIV. Dr. Monica Beg, Signe Rotberga UNODC

Wenz et al. BMC Public Health (2016) 16:927 DOI /s

Highlight underserved for screening, prevention and treatment of viral hepatitis B and C in Europe Ljubljana, Slovenia March 2016

Prevention of and Immunisation against Hepatitis B and C

Overview of drug-induced deaths in Europe - What does the data tell us?

New Brunswick Report on Sexually Transmitted and Blood Borne Infections, 2016

Minutes of the 18 th HIV/AIDS Think Tank Meeting 5 and 6 June 2012, Luxembourg

Prevention and control of Hepatitis B and C among vulnerable groups Estonia: People who use drugs

Crack Pipe FAQs: What service providers need to know. Presenter: Andrew Ivsins

Needle exchange programs

New EU Health Programme: funding mechanisms for civil society working on HIV and related areas

Blood Borne Viral Hepatitis Action for Wales Research Programme Developing the evidence base Findings, Implications and Recommendations

Stable incidence of hepatitis C virus infection among PWID in an Australian prison setting, : the HITS-p study

Hepatitis C. Kim Dawson October 2010

The evolution of the HIV/AIDS outbreak among IDUs in Romania

Technical Guidance Note for Global Fund HIV Proposals

Greater Manchester Commissioning Guidelines for Blood Borne Virus Prevention

QuADS Organisational Standards and Professional Competencies in needle exchange

WHAT WORKS? A comprehensive guide to safer needle and syringe selection for injecting drug users. tools for harm reduction

2 nd Meeting on detecting and responding to outbreaks of HIV among PWID

A handbook for people who have injected drugs

Prevention of and Immunisation against Hepatitis B and C

Drug Consumption Rooms: Legal barriers or just an excuse? Kirstie Douse Head of Legal Services Solicitor Advocate

Mercury : 1392BE15NP

Prevention of and Immunisation against Hepatitis B and C

Substance use and misuse

Methods: respondent driven sampling (RDS) was used to recruit PWID

Harm Reduction in Nigeria

Drugs. Cocaine is most commonly found in powder form and is snorted. Cocaine is a drug derived from the coca plant.

Safeworks and Harm Reduction

Harms and harm reduction workbook. Country X

Transmission/Prevention

At the dark end of the street A report on street based injecting in Dublin City Centre

NPS use in Lothian. Linda J Smith BBV Prevention Worker (RN/RMHN) Harm Reduction Team

Prevalence of HIV and risk behaviors among injecting drug users in Tallinn, Estonia in a series of cross-sectional studies

What is Hepatitis? easy read A B C

Greater Glasgow and Clyde. Blood Borne Viruses: Some important basic facts

Integrated harm reduction services for drug users and homeless people. Katrin Schiffer

Substance Misuse Treatment Framework (SMTF) Service Framework for Needle and Syringe Programmes in Wales

Under the Skin : Effective advocacy for HIV prevention in Canadian prisons

Strategies to Reduce Harm and HIV/AIDS Infection among Drug Using Populations

DISCLOSURE ESPACE GAIA, FIRST DCR IN PARIS SINCE OCTOBER /06/2017

Fax completed form to: (204) Further inquiries: your CD Coordinator

Additional North Carolina Projects

DRUCK-study Experiences from implementing user survey, rapid testing and risk counselling, involving trained agency staff

WHAT WORKS? A comprehensive guide to safer needle and syringe selection for injecting drug users. Second edition. Fully revised and updated

Eurasian Harm Reduction Network Hepatitis C transmission and injecting. responses

Building and enhancing capacity for HCV prevention; BC case scenario

PH52. Audit tool for the implementation of. NICE public health guidance 52 Needle and syringe programmes

Harm Reduction Database Wales: Needle and Syringe provision

Annual Reports Questionnaire (ARQ) Part III: Extent, patterns and trends in drug use

Methadone Treatment as a Harm Reduction Strategy, Gender Sensitive Programming and Evidence-based Strategies

Annual report 2012: the state of the drugs problem in Europe

Operational Guideline

The role of UNODC in working law enforcement agencies to promote harm reduction. IHRC, Bangkok, 23 April 2009

Viral Hepatitis. WHO Regional Office for Europe July 2013

Taking away the chaos The health needs of people who inject drugs in public places in Glasgow city centre

Frequently Asked Questions about Supervised Injecting Facilities 24 July 2014

Hepatitis C Basics. Michael Bailey Director of Programming, CATIE. Mary Choy Regional Health Education Coordinator, CATIE

I TRACK Survey. Report June 1, 2006

Transcription:

With financial support from the Drug Prevention and Information Programme of the European Union Strategies of drug users to avoid infection with hepatitis C Results from five European countries Dr. Heike Zurhold zurhold@uke.de Klinik für Psychiatrie und Psychotherapie Zentrum für Psychosoziale Medizin Zentrum für Interdisziplinäre Suchtforschung der Universität Hamburg

Background HCV is a major health concern Harm reduction (DCR, NSP, substitution treatment) has an impact on the reduction of HIV (prevalence is stabilizing across the EU below 10% But not on HCV Hepatitis C is still highly prevalent as on average 60% of IDUs in Europe are infected (EMCDDA 2010, Cornberg et al. 2011) Special groups at particular risk of infection Young drug users below the age of 25 Drug users injecting less than two years Low knowledge of HCV transmission and prevention

The European study Objectives 1. To review the evidence base for and practice of HCV prevention 2. To explore how the risk group of drug users manage to avoid an infection with hepatitis C 3. To develop recommendations for HCV prevention addressed to young DUs Approaches Part 1 Part 2 Part 3 Part 4 Part 5 Scientific evidence for effective for HCV prevention Collection of guidelines + standards for HCV prevention in each EU MS Overview on implemented HCV prevention measures in five EU regions / cities Interviews with young HCV-negative drug users and with experts Local conferences to present and discuss results

Partners and cities involved Germany: CIAR Hamburg drug treatment, HR, prison Netherlands: Mainline Foundation Amsterdam, Leiden, Almelo, Leeuwarden drug treatment, HR, prisons Lithuania: EHRN (Eurasian Harm Reduction Network) Vilnius, Klaipeda HR Catalonia: Barcelona Health Department of Catalonia Barcelona, Lleida, Sant Adrià del Besòs HR, prisons Greece: Kethea drug treatment provider 4 Kethea treatment & counselling centres in Piraeus, Athens

Methods for interviews with drug users Inclusion criteria: Current drug users who are below the age of 30 - has been extended to 35 hepatitis C negative or who are not sure if they are infected, use heroin, cocaine powder, crack or amphetamines regularly (at least 3 days a week) Structured questionnaire on Drug use behaviour Strategies to prevent infection with hepatitis C Knowledge on hepatitis C (quiz on HCV) Interviews were conducted under supervision and guidance of staff in lowthreshold centres, drug treatment, outreach work, counselling centres, prisons Intention was to include 100 drug users in each of the five European countries

Database - Questionnaires Germany Netherlands Lithuania Catalonia Greece Total N 66 21 89 97 104 377 Age 26.9 25.8 25.5 27.1 24.9 26 Female (%) 43.9 9.5 40.4 38.1 14.4 31.6 In last 12 months tested for (%) HIV 78.8 42.9 71.9 68.8 58.0 66.9 HBV 79.7 38.1 28.1 57.9 59.9 53.9 HCV 80.0 38.1 41.6 67.4 58.7 59.4 Infected with (%) HIV 1.5 (n=1) 0 0 3.1 (n=3) 0 1.1 HBV 3.0 0 6.7 4.2 1.0 3.5 HCV 0 0 0 0 0 0

Substances used (n=377) 89% 98% ever in past 30 days 69% 71% 66% 65% 49% 41% 46% 26% 17% 17% Alcohol Heroin Cocaine Crack Amphetamine Injected In past 30 days 69% used heroin mostly in Catalonia, followed by Greece 26% used cocaine most often in Germany and Catalonia 17% used crack mainly in Germany 17% used amphetamines mainly in Netherlands, followed by Lithuania

Routes of administration in past 30 days (n=294) Those who injected, smoked or sniffed substances in the past 30 days 98% injecting smoking sniffing 77% 84% 69% 62% 64% 46% 39% 51% 51% 39% 37% 23% 19% Germany (n=54) Netherlands (n=13) Lithuania (n=62) Catalonia (n=86) Greece (n=79) 2%

Risk behaviour in past 30 days (n=294) Happened at least once 30% 48% 38% 14% 13% use of syringes used by others use of needles used by others use of filter, spoon or water used by others Injected in past 30 days (n = 159) use of crackpipe or foil used by others Smoked in past 30 days (n = 136) use of sniffing equipment (tubes) used by others Sniffed in past 30 days (n = 138)

Risk behaviour and use of harm reduction Harm reduction services used in past 30 days Used by Injectors (n=254) Used by Non-injectors (n=129) Any service used 82% 61% Syringe exchange 59% 0 Received smoking foil 13% 36% Education for hygiene 30% 16% Advice on safer use 48% 26% Testing for HIV and hepatitis 54% 39% Use of services has helped to remain HCV-negative 57% 55% Currently in substitution treatment 40% 34% Months in substitution treatment 10.7 11.8

HCV-free years among IDUs who injected in past 30 days (n=169) 65% of all respondents have ever injected On average they inject since 5.3 years and remained negative for HCV Age at first regular injecting Years of injecting drugs 6.6 5.2 6,3 4.2 3.3 20.4 22.3 19.1 22 21.2 Germany (n=26) Netherlands (n=3) Lithuania (n=69) Catalonia (n=43) Greece (n==28)

Strategies to prevent HCV infection (n=377) Injectors (ever) Non-Injectors avoid blood contact 86% 87% take care for hygiene 81% 72% 36% only use my own equipment 74% avoid unstable housing /homelessness 42% 49% take myself time for drug use 28% 43% avoid withdrawal situations 33% 40% use less often on street 32% 41% do not inject drugs 84% 19% always use new needles + syringes 46% only share equipment with my partner 12% 14%

Main reasons for avoiding HCV infection Not sharing drug use equipment - appears to be very different Partly not sharing any equipment at all Partly not sharing needles Be the first one preparing the drug if sharing with others Smoking instead of injecting if no clean needles and syringes are available Avoid blood contact Safer sex Using drugs only alone, avoid contact with injectors Not sharing with those users known to be infected No tattoos in prison, not sharing razors Hygiene Try to avoid sharing of injecting and smoking equipment Only sharing with well known persons such as brother, partner Taking care for own body, using disinfectants Keeping distance to people infected

Summary Risk behaviour occurs Even though high risks such as sharing of needles and syringes is quite rare But sharing of paraphernalia and smoking equipment is rather widespread Main prevention strategies to remain HCV negative For injectors Utilisation of harm reduction services, in particular NSP, education in safer use and testing Avoid sharing of drug use equipment Take more time for drug use For smokers and sniffers Also testing Blood awareness = avoid blood contact, not injecting, hygiene = distance to injectors